PERRIGO Co plc
Perrigo Company plc (NYSE: PRGO) develops, manufactures and markets over-the-counter self-care products, including medicines for coughs, allergies, pain and digestive health, as well as infant formula, oral care, skin care, women’s health products and vitamins. Its Consumer Self-Care Americas segment serves the United… From the company’s description.
Over the twelve months to Sep 26, 2026, PERRIGO Co plc reported revenue of $4.09B, down 4.5% from a year earlier, and a net loss of $1.77B. Its operating margin was −39.4%, and operations generated $240.60M in cash. In fiscal 2025, it reported revenue of $4.25B, down 2.8% from fiscal 2024, and a net loss of $1.43B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PERRIGO Co plc does
In the company’s own words
Perrigo Company plc (NYSE: PRGO) develops, manufactures and markets over-the-counter self-care products, including medicines for coughs, allergies, pain and digestive health, as well as infant formula, oral care, skin care, women’s health products and vitamins. Its Consumer Self-Care Americas segment serves the United States and Canada, supplying retailers with store-brand products and selling a select range of its own brands. Consumer Self-Care International covers markets outside North America, primarily Europe and Australia, where the company sells branded products and store brands through pharmacies, wholesalers, retailers and e-commerce channels. Major brands include Compeed, Mederma, Opill, Solpadeine, Coldrex, Jungle Formula and ellaOne. Perrigo reports that Walmart accounted for 12.9% of consolidated net sales in 2025; its other customers include drug, grocery and mass-merchandise chains, wholesalers and online retailers. The company had approximately 8,100 employees across 31 countries as of December 31, 2025. Its website is www.perrigo.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- DUBLIN 2, L2
- Fiscal year end
- December
- CIK
- 1585364
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PERRIGO Co plc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PERRIGO Co plc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PERRIGO Co plc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PERRIGO Co plc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PERRIGO Co plc's last four quarterly filings that the numbers alone won't show?”